» Articles » PMID: 26401907

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Abstract

Objective: To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).

Methods: A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework.

Results: In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS.

Conclusion: These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.

Citing Articles

Global research trends in biological therapy for ankylosing spondylitis: A comprehensive visualization and bibliometric study (2004-2023).

He W, Yang H, Yang X, Huang J, Wu Z Hum Vaccin Immunother. 2025; 21(1):2445900.

PMID: 39813123 PMC: 11740677. DOI: 10.1080/21645515.2024.2445900.


Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study.

Kiltz U, Baraliakos X, Brandt-Jurgens J, Wagner U, Lieb S, Sieder C Ther Adv Musculoskelet Dis. 2024; 16:1759720X241255486.

PMID: 38846755 PMC: 11155364. DOI: 10.1177/1759720X241255486.


Stimulus-Responsive Hydrogels as Drug Delivery Systems for Inflammation Targeted Therapy.

Yu H, Gao R, Liu Y, Fu L, Zhou J, Li L Adv Sci (Weinh). 2023; 11(1):e2306152.

PMID: 37985923 PMC: 10767459. DOI: 10.1002/advs.202306152.


Comanagement with rheumatology and prescription biologics filled during pregnancy in women with rheumatic diseases: a retrospective analysis of US administrative claims data.

Shridharmurthy D, Lapane K, Baek J, Nunes A, Kay J, Liu S BMJ Open. 2022; 12(12):e065189.

PMID: 36549721 PMC: 9791456. DOI: 10.1136/bmjopen-2022-065189.


Inflammatory Bowel Disease: Focus on Enteropathic Arthritis and Therapy.

Barkhodari A, Lee K, Shen M, Shen B, Yao Q Rheumatol Immunol Res. 2022; 3(2):69-76.

PMID: 36465324 PMC: 9524814. DOI: 10.2478/rir-2022-0012.


References
1.
Guyatt G, Oxman A, Sultan S, Brozek J, Glasziou P, Alonso-Coello P . GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2012; 66(2):151-7. DOI: 10.1016/j.jclinepi.2012.01.006. View

2.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E . 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70(6):896-904. PMC: 3086052. DOI: 10.1136/ard.2011.151027. View

3.
Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

4.
Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6):777-83. DOI: 10.1136/ard.2009.108233. View

5.
Lautermann D, Braun J . Ankylosing spondylitis--cardiac manifestations. Clin Exp Rheumatol. 2002; 20(6 Suppl 28):S11-5. View